Landos Biopharma Inc
General ticker "LABP" information:
- Sector: Health Care
- Industry: Pharmaceuticals
- Capitalization: $16.6M
Landos Biopharma Inc follows the US Stock Market performance with the rate: 34.1%.
Estimated limits based on current volatility of 0.5%: low 22.31$, high 22.51$
Factors to consider:
- Current price 168.3% above predicted high
- Earnings for 3 months up through Q1 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term predictions were made for the period from 2023-12-31 to 2025-12-30
- 2023-12-31 to 2024-12-30 predicted range: [3.06$, 8.28$]
- 2024-12-30 to 2025-12-30 predicted range: [3.81$, 9.76$]
Financial Metrics affecting the LABP estimates:
- Negative: Non-GAAP EPS of -3.46 <= 0.08
- Negative: Operating Income to Revenue ratio of -1.00 <= 0.01
- Negative: Operating Cash Flow per share of -3.26 <= 0.20
- Negative: negative Net Income
- Negative: Industry Earnings per Price (median) of -0.18 <= 0.01
Short-term LABP quotes
Long-term LABP plot with estimates
Financial data
| YTD | 2021-12-31 | 2022-12-31 | 2023-12-31 |
|---|---|---|---|
| Operating Revenue | $18.00MM | $0.00MM | $0.00MM |
| Operating Expenses | $56.82MM | $40.56MM | $22.73MM |
| Operating Income | $-38.82MM | $-40.56MM | $-22.73MM |
| Non-Operating Income | $0.39MM | $1.28MM | $0.79MM |
| Interest Expense | $0.00MM | $0.58MM | $0.00MM |
| R&D Expense | $41.56MM | $25.68MM | $12.00MM |
| Income(Loss) | $-38.42MM | $-39.28MM | $-21.93MM |
| Profit(Loss) | $-38.42MM | $-39.28MM | $-21.93MM |
| Stockholders Equity | $76.27MM | $39.13MM | $31.79MM |
| Assets | $92.88MM | $45.25MM | $38.04MM |
| Operating Cash Flow | $-27.06MM | $-45.77MM | $-20.48MM |
| Investing Cash Flow | $-58.71MM | $74.06MM | $7.78MM |
| Financing Cash Flow | $91.61MM | $0.00MM | $13.57MM |
| Earnings Per Share* | $-9.50 | $-9.44 | $-3.50 |
* EPS are Split Adjusted, recent splits may be reflected with a delay.